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Aims The preferred antithrombotic strategy for secondary prevention in patients with cryptogenic stroke (CS) and patent
foramen ovale (PFO) is unknown. We pooled multiple observational studies and used propensity score-based methods
to estimate the comparative effectiveness of oral anticoagulation (OAC) compared with antiplatelet therapy (APT).
Methods
and results
Individual participant data from 12 databases of medically treated patients with CS and PFO were analysed with Cox
regression models, to estimate database-specific hazard ratios (HRs) comparing OAC with APT, for both the primary
composite outcome [recurrent stroke, transient ischaemic attack (TIA), or death] and stroke alone. Propensity scores
were applied via inverse probability of treatment weighting to control for confounding. We synthesized database-spe-
cific HRs using random-effects meta-analysis models. This analysis included 2385 (OAC ¼ 804 and APT ¼ 1581) pa-
tients with 227 composite endpoints (stroke/TIA/death). The difference between OAC and APT was not statistically
significant for the primary composite outcome [adjusted HR ¼ 0.76, 95% confidence interval (CI) 0.52–1.12] or for the
secondary outcome of stroke alone (adjusted HR ¼ 0.75, 95% CI 0.44–1.27). Results were consistent in analyses ap-
plying alternative weighting schemes, with the exception that OAC had a statistically significant beneficial effect on the
composite outcome in analyses standardized to the patient population who actually received APT (adjusted HR ¼ 0.64,
95% CI 0.42–0.99). Subgroup analyses did not detect statistically significant heterogeneity of treatment effects across
clinically important patient groups.
Conclusion We did not find a statistically significant difference comparing OAC with APT; our results justify randomized trials com-
paring different antithrombotic approaches in these patients.
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Clinical perspective
The preferred antithrombotic strategy for secondary prevention in patients with cryptogenic stroke and patent foramen ovale is unknown.
Current practice reflects this uncertainty, with antiplatelet therapy used in about two-thirds of patients and anticoagulation used in the
remainder. Our results show low outcome rates with both forms of antithrombotic therapy in these patients. The comparison between
treatments was not statistically significant in our main analyses but the treatment effect estimates favored oral anticoagulation, suggesting
that this approach deserves further investigation, particularly for novel oral anticoagulants with better therapeutic profiles than warfarin.
Introduction
With the exception of cardio-embolic stroke, in which oral antic-
oagulation (OAC) is the preferred antithrombotic strategy for
secondary prevention, guideline-recommended care for ischaemic
stroke patients generally includes antiplatelet therapy (APT).1
However, there is considerable disagreement over the best antith-
rombotic approach in patients with cryptogenic stroke (CS)
and patent foramen ovale (PFO), in which paradoxical embolism
is a suspected mechanism. Although the clinical syndrome caused
by paradoxical embolism is arterial occlusion, the thrombus
arises from a venous source. Thus, response to therapy may be
more analogous to that of venothromboembolic disease in which
OAC is superior.2
There has been no definitive study assessing the comparative
effectiveness of OAC vs. APT in this population. Recent trials
comparing mechanical PFO closure with ‘best medical therapy’
have generally left the choice of medical therapy to the treating phy-
sicians3 – 5 and included a substantial minority of patients receiving
warfarin instead of APT, indicating continued uncertainty.
A recent meta-analysis comparing OAC vs. APT using published
data from both randomized and (mostly) observational studies6
suggested substantial benefits from OAC; however, the total num-
ber of included patients was small (n ¼ 629) and the component ob-
servational studies made no attempt to control for confounding. It
has been shown that patients receiving different antithrombotic re-
gimens are non-comparable.7 Herein, we present the findings of
the Targeted Antithrombotic Therapy in Cryptogenic Stroke with
PFO (TAcTiCS-PFO) study, which addresses the limitations of the
prior analyses by obtaining individual participant data (IPD) from
studies included in the original meta-analysis; substantially augment-
ing the data set with studies participating in the Risk of Paradoxical
Embolism (RoPE) study8,9; and using rigorous methods to control
confounding.
Methods
Construction of the IPD database
Study selection criteria
The studies included in the TAcTiCS-PFO study partially overlap with
those included in the RoPE study.8,9 Studies were eligible for the present
investigation if they enrolled CS patients systematically investigated for
PFO (with transoesophageal echocardiography or transcranial Dop-
pler), included at least 15 patients with PFO and CS receiving APT
and at least 15 patients with PFO and CS receiving OAC, and obtained
1-year follow-up data for transient ischaemic attack (TIA), stroke, or
death on at least 90% of the consenting subjects.
Identifying studies meeting selection criteria and
obtaining data
Appropriate studies were identified by literature search and through
direct contact with RoPE study investigators. Although the literature in-
cluded only 8 studies that reported comparative data on APT vs. OAC,
we identified 18 studies that potentially had collected data appropriate
for comparative analysis. Seven of these were already included in the
RoPE study (five other RoPE databases did not meet inclusion criteria).
Of the remaining 11 studies, only 2 met our inclusion criteria, had suf-
ficient available data, and agreed to participate. Finally, we were also able
to obtain the medical arms of the three randomized clinical trials testing
mechanical closure.3– 5 Thus, the final TAcTiCS-PFO data set included
12 component databases (Table 1).
Harmonizing data across contributed databases
Common variable definitions established for the RoPE study formed the
basis for harmonization of data in TAcTiCS-PFO and have been de-
scribed previously.8,9
Our primary outcome was a composite of stroke, TIA, or death from
any cause; stroke alone was considered as a secondary outcome. We
defined stroke as a sudden onset neurological deficit in a vascular terri-
tory presumed to be due to focal ischaemia lasting.24 h or accompan-
ied by acute neuroimaging changes in the appropriate location; TIA was
defined as a deficit lasting ,24 h, unaccompanied by acute neuroima-
ging changes in the appropriate location. Our definition of CS con-
formed to the Trial of ORG 10172 in Acute Stroke Treatment
(TOAST) classification,10 which requires a complete work-up to identify
underlying causes including (at minimum) magnetic resonance or com-
puted tomography imaging; vascular imaging with angiography; and car-
diac rhythm study (by electrocardiography, Holter, or telemetry).
Cardio-embolic stroke in the TOAST classification is considered ‘prob-
able’ if a high-risk source is identified and ‘possible’ if medium-risk
sources are present. This latter category includes PFO and atrial septal
aneurysms (ASAs). Study subjects with medium-risk sources were
considered cryptogenic. All included studies conformed to this CS
definition.
Safety was examined by comparing major bleeding classified as ser-
ious adverse events, using the definitions in the component studies.
This information was reliably obtained only in the four randomized trials
(PICSS, CLOSURE, RESPECT, and the PC Trial).
Exposure to treatment was determined on the basis of the initial oral
antithrombotic regimen after the index event. Thus, the OAC treatment
group included the strategy of initial OAC treatment, with eventual
switching to APT. We describe switching behaviour in the three trials
examining PFO closure (CLOSURE, RESPECT, and the PC Trial), in
which ascertainment of these data was most complete. For patients
started on OAC, switching was defined as the first visit without an
anticoagulant but with an antiplatelet. For patients started on APT,
switching was defined as any visit with an OAC, either as monotherapy
or as dual antithrombotic therapy. OAC included only warfarin. APT
included aspirin, clopidogrel, ticlopidine, and aspirin combined with
D.M. Kent et al.2382
dipyridamole. In our main analysis, we excluded patients who were
initially placed on combination antiplatelet/anticoagulant therapy. We
assessed the stability of our results by repeating the analysis after
reclassifying these patients as anticoagulant-treated.
Database-specific treatment effects and
average effects across studies
Propensity score analyses
We estimated the effect of OAC vs. APT on the outcomes of interest
using a two-stage process. In the first stage, database-specific analyses
were used to estimate marginal hazard ratios (HRs) comparing the
two treatments. In the second stage, the HR estimates were pooled
across databases.
To adjust for confounding bias within each of the included studies,
database-specific HRs were estimated using inverse probability of
treatment-weighted Cox regression.11 First, we derived propensity
scores via logistic regression (with OAC use as the response) to esti-
mate each patient’s probability of being assigned to OAC.12 In the
next step, this score is applied to weight patients by the inverse of the
probability of receiving the treatment that they actually received. This
method creates balance for all the covariates across the two treatments,
to efficiently control for confounding. Supplementary material online,
Table S1A–L describes the variables included in each database-specific
propensity score model. Briefly, variables with .20% missing data
were excluded from these analyses, except for categorical variables,
in which an indicator variable was created for missingness where miss-
ingness was no greater than 40%. All variables that might plausibly influ-
ence treatment choice and the outcome of interest were included in the
propensity score model; variable selection was based on clinical reason-
ing and not statistical signficance.13
Patients receiving OAC were weighted by inverse probability of
treatment weights calculated as pOAC/pi and patients receiving APT
were weighted by (12pOAC)/(12pi); here pOAC is the probability of
receiving OAC in the sample and pi is the individual’s propensity for
receiving OAC (estimated on the basis of patient characteristics).14
These weights yield an estimate of the average treatment effect
standardized to the overall study population. For each database, we
assessed whether the estimated propensity score produced balance
(in each of the studies separately and in the overall database) by exam-
ining the standardized mean difference for all covariates included in the
propensity model.
In all analyses, the standard error of the database-specific HR was ob-
tained using the robust covariance matrix estimate.15 Because extreme
weights can influence the estimate of the treatment effect, the distribu-
tions of propensity weights in each database were examined; individuals
assigned weights greater than 10 or less than 0.1 were trimmed or trun-
cated in sensitivity analyses.16
Meta-analyses
We estimated summary treatment effects across studies using a two-
level univariate random-effects meta-analysis model to combine the
propensity score-weighted estimates of the log HR from each of the in-
cluded studies.17 We assessed between-study heterogeneity by calcu-
lating the I2 index for each meta-analysis.18
Exploring treatment effect heterogeneity
RoPE strata-specific effects and other subgroups
The 10-point RoPE score (Supplementary material online, Table S2) was
used to stratify the population based on the estimated probability that
the index stroke was PFO-attributable, as opposed to a stroke of
another (occult) cause with an incidentally discovered PFO.19 The
calculation of the attributable fraction is based on a comparison of
PFO prevalence between CS patients and similar patients without CS.
Generally, with a decreasing number of conventional stroke risk factors
and younger age (resulting in a higher RoPE score and an increasing PFO
prevalence in CS patients), the PFO-attributable fraction increases.
To examine whether OAC treatment effects might differ between
patients with high vs. low RoPE scores, we excluded two databases
for which neuroradiology variables were not obtained (Sapienza and
PC Trial) and calculated RoPE scores on all the remaining patients. Be-
cause some patients had missing data for RoPE score variables, we used
multiple imputation within each data set. We stratified patients within
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Table 1 Component databases of the TAcTiCS-PFO study
Study Subjects (n) Antiplatelets n (%) Anticoagulants n (%) Outcomes of interest (n)
Stroke Stroke/
TIA
Death Stroke/TlA/
death
RESPECT (medical arm)3 438 332 (75.8%) 106 (24.2%) 13 17 1 17
CLOSURE 1 (medical arm)5 379 265 (69.9%) 114 (30.1%) 12 25 3 27
German31 296 161 (54.4%) 135 (45.6%) 16 27 11 33
CODICIA32 294 212 (72.1%) 82 (27.9%) 6 16 3 19
PC Trial (medical arm)4 205 141 (68.8%) 64 (31.2%) 7 11 0 11
Bern Published33 146 67 (45.9%) 79 (54.1%) 16 28 9 33
FORI34 117 93 (79.5%) 24 (20.5%) 8 10 1 11
Sapienza35 115 80 (69.6%) 35 (30.4%) 4 7 5 9
Schuclenz, 200536 113 66 (58.4%) 47 (41.6%) 8 29 2 31
PICSS25 98 56 (57.1%) 42 (42.9%) 10 16 4 20
Tufts37 95 46 (48.4%) 49 (51.6%) 3 4 0 4
Toronto38 89 63 (70.8%) 26 (29.2%) 6 11 2 12
Total 2385 1582 (66.3%) 803 (33.7%) 109 201 41 227
Patients treated with both antiplatelets and anticoagulants were excluded from this table.
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each imputed data set into strata with RoPE score ≥7 and ,7. In the
RoPE study, patients with a score of 7 were estimated to have a
.70% PFO-attributable fraction, and this value separated patients
into similarly sized groups.
To control for confounding, propensity scores for treatment were
created for each stratum within each imputed data set20 and used to
weight observations as described earlier. HRs were calculated within
each imputed data set and combined.21 Database- and stratum-specific
HRs were then meta-analyzed. Stratified analyses were similarly per-
formed to estimate differential effects across the following subgroups:
age groups (≤45 and .45); sex; presence vs. absence of ASA; presence
vs. absence of a superficial lesion on neuroimaging; and presence vs.
absence of large shunt (defined as .10 microbubbles in left atrium
within three cardiac cycles).
In stratified analyses, some of the studies did not have adequate data
to estimate effects in all subgroups. To make maximal use of the avail-
able data, we used a bivariate random-effects meta-analysis model. This
model allows for heterogeneity of the ‘true’ treatment effects across
studies (within each subgroup) and accounts for possible correlations
of these effects across studies.22 All meta-analysis models were fit
with restricted maximum likelihood methods.23
Sensitivity analyses
We performed extensive sensitivity analyses. First, because clinicians
may recommend a specific therapy based on clinical characteristics
associated with treatment response, we explored alternative propensity
weighting schemes that standardized treatment effects to the patient
populations who actually received OAC or APT.24 Secondly, we per-
formed a meta-analysis that included treatment effect estimates
from studies that did not provide individual-level data for TAcTiCS
PFO, but provided enough information to approximate them from
published data. Thirdly, we performed analyses limited to data from
the four randomized trials participating in TAcTiCS,3 – 5,25 assuming
that outcome ascertainment methods were more rigorous in these
studies.
Software
Study-level analyses were conducted using SAS software, version 9.4 TS
Level 1 M1 (SAS Institute Inc., Cary, NC, USA). Meta-analyses were con-
ducted using Stata, version SE/13.1 (Stata Corp., College Station, TX,
USA).
Results
We obtained data from 2385 patients (OAC ¼ 803 and APT ¼
1582) followed for a total of 6116 person-years with 227 composite
endpoint events (stroke/TIA/death) (Figure 1) . The crude outcome
rates were 3.7% events per person-year for the composite outcome
and 1.8% for recurrent stroke. The rate of OAC use among those
receiving antithrombotic treatment ranged from 20.5% (in FORI)
to 54.1% (in Bern) (Table 1). Among patients in the medical arms
of the three device trials, 30% of those initiated on OAC eventually
switched to APT (i.e. at least one follow-up visit with only APT),
whereas only 7% on those initiated on APT subsequently received
OAC (either as an additional agent or as monotherapy for at least
one visit).
Patient characteristics are summarized in Table 2 (database-
specific comparisons are presented in Supplementary material
online, Tables S1A–L). Compared with patients initially receiving
APT, patients receiving OAC were older, more likely to have an
index stroke, more likely to have a history of stroke, and greater
stroke severity. On neuroimaging, patients receiving OAC were
more likely to have superficial, anterior, multiple, and large lesions.
Echocardiographic characteristics also differed, with patients receiv-
ing OAC being more likely to have an ASA and larger shunt. Overall,
there was no substantial difference in the distribution of vascular risk
factors or RoPE scores across treatment groups. Despite the sub-
stantial differences seen between the treatment groups, inverse
probability weighting achieved balance in the covariates in the indi-
vidual databases and overall.
Database-specific propensity models contained from 10 to 34
variables and had C-statistics ranging from 0.66 (RESPECT) to 0.82
(Tufts). Although propensity adjustment had considerable influence
over the HR estimate in individual studies, confounding bias
appeared to affect study-level effects in both directions; summary
results were similar in adjusted and unadjusted analyses and not stat-
istically significant in either (adjusted HR for the primary composite
outcome ¼ 0.76, 95% CI 0.52–1.12) (shown in Figure 2 and Table 3).
Similar results were seen for the outcome of stroke alone (adjusted
HR ¼ 0.75, 95% CI 0.44–1.27) (Supplementary material online, Fig-
ure S1). Results were similar when the 114 patients treated on com-
bination therapy (excluded from the primary analysis) were included
in the OAC group.
Overall, results were similar across alternative weighting schemes
(Table 3), with the exception that OAC had a statistically significant
beneficial effect on the primary composite outcome in analyses
standardized to the patient population who actually received APT
(adjusted HR ¼ 0.64, 95% CI 0.42–0.99). Point estimates of the
treatment effect standardized to the OAC-treated population did
not favor either antithrombotic approach. Results were similar to
the main analysis when estimates from the four literature-based
studies with unavailable individual patient data were included
(summary HR for primary composite outcome ¼ 0.76, 95% CI
0.54–1.07; summary HR for stroke alone ¼ 0.67, 95% CI 0.42–
1.08). Results were also similar in analyses restricted to data from
randomized trials (PICSS and the medically treated groups from
the three randomized trials of PFO closure). We subsequently
stratified patients by their RoPE score. About 1061 patients with
39 outcomes were in the high RoPE score group, and 1196 patients
with 115 composite outcomes were in the low RoPE score group.
Of the 128 patients who could not be classified because of missing
RoPE score variables, 77 patients were classifiable using imputation
and 49 patients were not (as they came from studies without neu-
roimaging data).
We did not find statistically significant heterogeneity of treatment
effects (i.e., effect modification) in any of the subgroup analyses for
the primary composite outcome (Figure 3). We obtained similar re-
sults for stroke (Supplementary material online, Figure S2). Of note,
outcome rates were very low among the high RoPE score group,
making the database-specific HRs inestimable in some studies and
resulting in imprecise effect estimates in others.
Bleeds classified as serious adverse events were ascertained in
1120 patients across four studies. There were only 10 such bleeds
in total, with very similar event rates in both groups (unadjusted
HR ¼ 0.91, 95% CI 0.22–3.74; adjusted HR ¼ 0.80, 95% CI 0.21–
3.1) (analysis details are provided in the Supplementary material
online, Table S3).
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Discussion
Our individual patient data meta-analysis incorporating 12 studies
with over 2000 patients did not detect a statistically significant differ-
ence in the composite outcome of stroke, TIA, or death with OAC
vs. APT in patients with CS and PFO. This is the largest study to date
examining medical therapy in this population. In general, point esti-
mates favoured OAC, with an estimated effect showing about 25%
relative reduction in the hazard of the composite outcome, but
these estimates were imprecise and confidence intervals did not
exclude the null. As the crude outcome rate overall was 3.7% per
person-year, we note that such a difference might be clinically
important. Sensitivity analyses were generally consistent with these
overall results, and subgroup analyses did not identify statistically
significant heterogeneity of treatment effects.
Prior evidence was suggestive that warfarin may be more effective
for secondary stroke prevention in these patients. Although the
randomized trial PICSS25 (which examined the subgroup of patients
from WARSS26 investigated for PFO) found no benefit for warfarin
over aspirin, it included only 98 patients with both PFO and CS.
Among these patients, a clinically substantial, but not statistically sig-
nificant, benefit was observed for warfarin (stroke or death in 9.5 vs.
17.9% of warfarin- and ASA-treated patients, respectively; HR ¼
0.52, P ¼ 0.28). We recently synthesized the published evidence
on secondary stroke prevention in patients with PFO and CS and
found a clinically impressive and statistically significant 50% reduc-
tion in recurrence risk with warfarin.6 Finally, in the RESPECT trial,
patients with APT but not with OAC fared significantly worse than
those with device closure in a prospectively planned subgroup
analysis.4
The TAcTiCS study reported here has several advantages over
prior meta-analyses using published data. Most importantly,
although the seven previously published comparative studies did
not control for confounding by indication (because outcomes within
Figure 1 Flow diagram showing cases included in the TAcTiCS analysis and detailing reasons for exclusion of potentially eligible participants
from the 12 component studies.
Anticoagulant vs. APT in patients with CS and PFO 2385
component studies were too few to support conventional risk ad-
justment), we used methods for confounding control that rely on
exposure (rather than outcome) modeling. Our analyses showed
that the treatment groups in the component databases differed
with respect to many potential confounding variables, making un-
adjusted analyses suspect. Moreover, previous meta-analyses in-
cluded only 629 patients; the current analysis included almost
four-fold the number of patients.6 Finally, because studies enrolled
patients at or near the time of the index event, our study approxi-
mates a ‘new (incident) user’ design.
Analysis of individual patient data also permitted the examination
of the effect of treatment in population subgroups. Our hypothesis
that OAC would be especially beneficial for patients in the ‘purer’
high RoPE score group (who have a low burden of vascular risk
factors) was not borne out. Although this group presumably is en-
riched with patients whose index event was caused by paradoxical
embolism, the low RoPE score group may have been enriched with
occult atrial fibrillation, given the strong association of this dysrhy-
thmia with age and vascular risk factors and variability across
component studies in the duration electrocardiograph monitoring
to rule out atrial fibrillation as a stroke aetiology. Regardless, the
treatment effect was not statistically significant in either subgroup.
Although this study represents the best-available evidence on the
comparative effectiveness of APT compared with OAC for patients
with CS and PFO, some limitations need to be considered. First, our
results estimate the effect of initial antithrombotic choice; they are
analogous to an intention-to-treat analysis in a randomized trial.
However, a substantial minority of patients who started OAC sub-
sequently switched to APT, potentially attenuating the difference
between treatment groups. Second, safety outcomes were not
consistently obtained across most of the studies. Third, this was a
non-randomized observational study. Although propensity score-
based weighting achieved balance in the observed covariates across
component databases, the effect of unmeasured covariates cannot
be assessed. Although theory and simulations support the advantage
of propensity score-based methods over conventional regression
methods, empirical work has shown that the results of propensity
score-based observational comparative effectiveness studies
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Table 2 Patient characteristics across TAcTiCS component databases using non-imputed data
Variable Treated with anticoagulants
(n5 803)
Treated with antiplatelets
(n5 1582)
P-valuea Full cohort (n 5 2385)
Clinical variables
Ageb 50.1+13.2 (803) 48.4+13.1 (1576) 0.0034 49.0+13.2 (2379)
Male gender 57.9% (465/803) 56.6% (895/1580) 0.5562 57.1% (1360/2383)
White race 87.5% (210/240) 85.2% (381/447) 0.4143 86.0% (591/687)
Index event of stroke 81.5% (626/768) 76.9% (1155/1501) 0.0123 78.5% (1781/2269)
Prior stroke/TIA 19.1% (153/803) 15.2% (239/1576) 0.0156 16.5% (392/2379)
Initial NIHSSb 2.7+3.7 (546) 1.5+2.5 (992) ,0.0001 1.9+3.0 (1538)
Initial Rankinb 0.7+1.1 (506) 0.7+0.9 (1025) 0.078 0.7+1.0 (1531)
Current smoker 23.0% (184/801) 22.3% (350/1572) 0.3615 22.5% (534/2373)
History of hypertension 31.2% (250/802) 32.4% (511/1577) 0.5428 32.0% (761/2379)
History of diabetes 7.9% (63/800) 7.5% (119/1578) 0.7724 7.7% (182/2378)
Hypercholesterolaemia 29.9% (202/675) 34.1% (446/1309) 0.0621 32.7% (648/1984)
Migraine 24.5% (140/572) 24.1% (300/1246) 0.8539 24.2% (440/1818)
Body mass indexb 27.4+5.1 (285) 27.4+5.4 (515) 0.8981 27.4+5.3 (800)
Neuroradiology
Superficial (vs. deep) 54.1% (320/592) 47.2% (573/1215) 0.0059 49.4% (893/1807)
Anterior infarct 44.1% (200/454) 34.2% (290/848) 0.0005 37.6% (490/1302)
Multiple strokes (vs. not) 11.5% (55/478) 4.9% (46/933) ,0.0001 7.2% (101/1411)
Large infarct (vs. small) 33.0% (169/512) 22.5% (218/971) ,0.0001 26.1% (387/1483)
Echocardiography
Hypermobile septum 36.4% (285/783) 26.2% (401/1532) ,0.0001 29.6% (686/2315)
Large PFO 62.8% (389/619) 56.9% (684/1202) 0.0147 58.9% (1073/1821)
RoPE scoreb 6.3+1.7 (588) 6.4+1.8 (1201) 0.3439 6.4+1.7 (1789)
RoPE ≥ 7, % (n)c 43.1% (341/791) 46.1% (720/1561) 0.1652 45.1% (1061/2352)
aP-value from two-sample t-test when mean+ standard deviation (n) shown, non-parametric Kruskal–Wallis test when median ,25th–75th percentile (n) shown, and x2 test
otherwise when data shown are presented as % (ratio) or % (n).
bMean+ standard deviation.
cIncludes cases with missing data needed for RoPE score, but still classifiable as ≥7 vs. ≤6.
D.M. Kent et al.2386
Figure 2 Summary results for composite outcome by study. Open circles represent crude HRs for individual studies; solid circles represent the
adjusted HRs in individual studies. Pooled estimates, represented by diamonds, were computed from a random-effects model. Horizontal lines
through the circles and diamonds denote the 95% CIs for individual studies and summary results, respectively.
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Table 3 Main and sensitivity analyses
Weighting schemes Stroke/TIA/death Stroke alone
HR (95% CI) P-index (%) HR (95% CI) P-index (%)
Main analysis
Standardized to the overall population 0.76 (0.52–1.12) 0 0.75 (0 44–1.27) 0
Sensitivity analyses
Standardized to the antiplatelet-treated 0.64 (0 42–0.99) 0 0.60 (0.33–1.10) 19
Standardized to the anticoagulant-treated 1.01 (0.60–1.69) 40 1.04 (0.47–2.30) 45
Standardized to the overall population, limited to RCTs 0.63 (0.23–1.71) 0 0.53 (0.14–2.04) 0
Standardized to the overall population, including data from published studiesa 0.76 (0.54–1.07) 0 0.67 (0 42–1.08) 0
CI, confidence interval; HR, hazard ratio; reference category is APT; TIA, transient ischaemic attack.
aThese analyses include data from published studies that did not contribute IPD to the RoPE database (for stroke/death/TIA: Harrer,39 Hausmann,40 and Cerrato41; for stroke alone:
Hausmann,40 Cerrato,41 and Lee.42)
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sometimes disagree with randomized study results.27,28 Fourth, the
quality of study procedures can vary from database to database, with
variable patient selection criteria, rates of loss to follow-up, and out-
come ascertainment methods across databases. However, for a sen-
sitivity analysis based on the databases derived from randomized
clinical trials, the results remained not statistically significant
although the point estimate favoured OAC more strongly.
Despite the fact that this is the largest study comparing antith-
rombotic strategies for secondary prevention of CS in patients
with PFO, the confidence intervals of our effect estimates were
wide and did not rule out clinically important benefits of OAC
over APT. This was particularly the case for key subgroups, such
as patients with high RoPE scores, in which outcome rates in both
treatment groups were very low. The imprecision of treatment ef-
fect estimates was in part due to the need to adjust for a large num-
ber of potential confounders that differed in distribution between
the treatment groups. Randomized clinical trials would be antici-
pated to provide more precise treatment effect estimates, even
with similar sample sizes and event rates.
Despite our results, the pathophysiological rationale supporting
OAC over APT for patients with non-lacunar ischaemic stroke with-
out a defined source (including those with PFO) is compelling. For
thrombo-embolic syndromes thought to be due to platelet-poor
thrombus formation occurring at venous flow rates (deep venous
thrombosis and pulmonary embolism) and in areas of haemostasis
(e.g. left atrial appendage in atrial fibrillation), warfarin has shown
consistent superiority to APT.2,29 The advent of novel antico-
agulants has renewed interest in the potential advantages of OAC
for secondary prevention in the CS population and has led to the
newly proposed diagnostic category of embolic stroke of undeter-
mined source as a potential therapeutic target.30 Although our re-
sults have not ruled out these benefits, the low outcome rates on
APT, particularly in younger patients without atherosclerotic risk
factors, limit the magnitude of the potential absolute benefit of
OAC in this setting.
Conclusion
In summary, currently available data do not provide definitive evi-
dence on the comparative benefits of OAC vs. APT in patients
with CS and PFO. Low outcome rates and the non-comparability
of treatment groups resulted in imprecise estimates of the compara-
tive effectiveness of antithrombotic treatments in this patient popu-
lation. These results support the need for additional comparative
studies, including randomized trials.
Supplementary material
Supplementary material is available at European Heart Journal online.
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